Novo Nordisk's CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide in a single once-weekly injection. The REDEFINE Phase 3 program has begun reporting results, and the mechanism is scientifically fascinating.

Background on amylin: Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. It slows gastric emptying, suppresses glucagon, and acts on area postrema and hypothalamic nuclei to promote satiety[1]. Pramlintide (Symlin) was approved in 2005 but failed commercially due to TID dosing and only modest weight loss.

Cagrilintide is an acylated amylin analog engineered for once-weekly dosing. The Phase 2 data for CagriSema showed impressive weight loss:

Phase 2 CagriSema results (Enebo et al., Lancet 2024):[2]

• CagriSema 2.4/2.4 mg: -15.6% at 32 weeks (vs -5.1% placebo)
• Curves still declining at 32 weeks — no plateau

The REDEFINE-1 Phase 3 trial (obesity without diabetes) reported topline results showing approximately 22-23% weight loss at 68 weeks. This would position CagriSema between semaglutide alone (~15%) and tirzepatide (~21%) in efficacy.

The key question: does the amylin pathway offer something mechanistically distinct from GIP agonism, or is this just another way to get to the same ~20% weight loss ceiling?

The mechanism question is important. GLP-1 and amylin act on overlapping but distinct CNS circuits. GLP-1 receptors are concentrated in the nucleus tractus solitarius (NTS) and arcuate nucleus. Amylin receptors (calcitonin receptor + RAMP complexes) are densely expressed in the area postrema and also the NTS, but with distinct downstream signaling[3].

Preclinical data consistently shows that GLP-1 + amylin co-agonism produces supra-additive weight loss compared to either alone. The proposed mechanism is convergent activation of anorexigenic neurons through parallel pathways — essentially hitting the satiety system from two different angles simultaneously.

Contrast this with GLP-1 + GIP (tirzepatide). GIP agonism appears to enhance GLP-1's effects partly through improved GLP-1 receptor trafficking and partly through independent adipose tissue effects. But the exact mechanism of GIP's contribution to weight loss is still debated — some researchers argue GIP antagonism could be equally effective, which is conceptually confusing.

Amylin agonism has a clearer mechanistic rationale for additive anorectic effects. Whether this translates to better durability or different metabolic outcomes (beyond weight loss) is what Phase 3 will tell us.

Let me contextualize the REDEFINE-1 topline result (~22.7% weight loss at 68 weeks). Head-to-head comparison at similar timepoints:

• Semaglutide 2.4 mg (STEP 1): -14.9% at 68 weeks
• Tirzepatide 15 mg (SURMOUNT-1): -20.9% at 72 weeks
• CagriSema 2.4/2.4 mg (REDEFINE-1): ~-22.7% at 68 weeks

So CagriSema appears to slightly edge out tirzepatide, but cross-trial comparisons are inherently unreliable due to different patient populations, baseline BMI distributions, and trial conduct. We need head-to-head data.

Interestingly, Novo Nordisk has a head-to-head trial of CagriSema vs tirzepatide 15 mg (REDEFINE-4, I believe). If CagriSema demonstrates non-inferiority or superiority to tirzepatide in a head-to-head, that would be a major commercial and scientific result. But this trial won't report until 2026-2027.

The tolerability profile is what I'm watching closely. In the Phase 2 data, GI adverse events with CagriSema were:

• Nausea: 47%
• Vomiting: 20%
• Diarrhea: 23%

These are broadly similar to semaglutide alone and perhaps slightly higher. The concern is that amylin's primary pharmacological effect includes slowed gastric emptying — the same mechanism that contributes to nausea. Adding amylin agonism to a GLP-1 RA might create additive GI side effects.

In clinical practice, GI tolerability is often the rate-limiting factor. If CagriSema gives 22% weight loss but 50% of patients have significant nausea, real-world effectiveness (accounting for discontinuation) might not be much better than semaglutide alone.

Fair concern, but the Phase 3 REDEFINE trials use a more gradual dose escalation schedule than Phase 2, which should improve tolerability. Novo Nordisk has learned from the semaglutide experience — slower titration consistently reduces GI side effects at the cost of slower time-to-effective-dose.

The more interesting safety signal with amylin analogs is injection site reactions. Cagrilintide can cause injection site nodules due to local amyloid-like aggregation[4]. In Phase 2, ~10% of CagriSema patients reported injection site reactions vs ~3% with semaglutide alone. These are generally mild and self-limiting, but they're something to monitor in Phase 3.

Also worth noting: amylin receptor agonism is conceptually different from GIP receptor agonism in terms of long-term risks. We have decades of data on native amylin physiology and years of data on pramlintide. The long-acting pharmacology of cagrilintide is new, but the target is well-characterized.